Cyclic vomiting syndrome plus

Richard G Boles1, Amy L R Powers, Kathleen Adams

  • 1Division of Medical Genetics, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA. rboles@chla.usc.edu

Insights

Cyclic vomiting syndrome with neuromuscular disease (CVS plus) presents a distinct phenotype. It shows earlier onset and increased comorbidities, possibly linked to mitochondrial dysfunction.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Cyclic vomiting syndrome (CVS) is a disabling childhood condition with episodes of nausea and vomiting.
  • A subset of CVS patients (25%) exhibit coexisting neuromuscular disease, termed CVS plus.
  • The distinctiveness of CVS plus within the broader CVS spectrum requires investigation.

Purpose of the Study:

  • To determine if CVS patients with neuromuscular disease (CVS plus) represent a distinct subentity.
  • To compare clinical characteristics between CVS plus and CVS without neuromuscular disease (CVS minus).

Main Methods:

  • A clinical interview was conducted with 80 CVS sufferers from a disease association database.
  • Subjects were categorized into CVS plus (≥2 neuromuscular manifestations) and CVS minus (0 manifestations).
  • Neuromuscular disease manifestations were assessed, including cognitive, skeletal, cranial nerve, and seizure disorders.

Main Results:

  • Neuromuscular disease manifestations clustered together in subjects.
  • CVS plus patients had an earlier age of onset for vomiting episodes.
  • CVS plus showed a 3-8 fold increased prevalence of dysautonomia and constitutional disorders, but similar sibling recurrence of neuromuscular disease.

Conclusions:

  • CVS plus represents a distinct phenotypic entity, not necessarily genetically distinct from CVS minus.
  • CVS plus predicts earlier disease onset and increased comorbidity with specific medical conditions.
  • Mitochondrial dysfunction may underlie the distinct phenotype observed in CVS plus.

Related Concept Videos

Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through interaction...
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...